Calliditas Therapeutics AB ADR (CALT) Social Stream



Calliditas Therapeutics AB ADR (CALT): $19.00

1.53 (-7.45%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add CALT to Watchlist
Sign Up

CALLIDITAS THERAPEUTICS AB (CALT) Price Targets From Analysts

Use the tables below to see what analysts covering CALLIDITAS THERAPEUTICS AB think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-19 4 $55 $48 $51.75 $25.655 101.72%
2021-12-15 4 $56 $48 $52 $25.655 102.69%
2021-12-17 4 $59 $52 $55.5 $25.655 116.33%
2022-01-13 4 $62 $55 $58 $25.655 126.08%
2022-02-24 3 $59 $55 $56.666 $25.655 120.88%
2022-11-14 3 $60 $55 $57 $25.655 122.18%
2023-01-03 3 $57 $55 $56 $25.655 118.28%
2023-02-23 4 $57 $55 $56 $25.655 118.28%
2023-02-24 4 $79 $53 $60.75 $25.655 136.8%
2023-05-16 6 $79 $18 $52.4 $25.655 104.25%
2023-08-17 6 $79 $18 $51.833 $25.655 102.04%
2023-11-09 6 $79 $18 $50.166 $25.655 95.54%
2023-12-20 6 $55 $18 $40.833 $25.655 59.16%

The Trend in the Analyst Price Target


CALT's average price target has moved down $12.83 over the prior 170 days.

CALT reports an average of 180.25% for its upside potential over the past 43 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-02-23 4 57 55 56.000 19.99 180.14%
2023-05-16 6 79 18 52.200 21.17 146.58%
2023-05-16 5 79 18 52.400 21.17 147.52%
2023-08-21 6 79 18 50.166 17.44 187.65%
2023-11-09 6 55 18 40.833 16.80 143.05%

CALT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.33 5 0 1 0 0 6

The Trend in the Broker Recommendations


Over the past 26 weeks, CALT's average broker recommendation rating improved by 0.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, CALLIDITAS THERAPEUTICS AB's variance in analysts' estimates is lower than -697.48% of them.
  • CALT has a higher number of analysts covering the stock than 300.76% of all US stocks.
  • CALT has a greater average analyst price target than 1570.12% of stocks in the small market cap category.
  • In terms of how CALLIDITAS THERAPEUTICS AB fares relative to stocks in the small market cap category, note that its upside potential (average analyst target price relative to current price) is greater than 970.34% of that group.

Stocks similar to CALLIDITAS THERAPEUTICS AB in the Pharmaceutical Products industry regarding analyst recommendations and price targets are RNA, GBIO, and RPTX.

Is CALT a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!